Nilofabicin

DB12347InvestigationalSmall molecule

CG400549 has been used in trials studying the treatment of Skin Infection.

Mechanism: Pharmacologically active on Enoyl-[acyl-carrier-protein] reductase [NADPH] FabI
Curator reviewed
Formula / weight: C₁₉H₂₀N₂O₂S · 340.439 g/mol (avg)
Code names: CG-400549

Resolves to

Compound

Structure

InChIKeyYCLREGRRHGLOAK-UHFFFAOYSA-NSMILESCC1=C(CN2C=CC(OCCC3=CC=CS3)=CC2=O)C=CC=C1N

Targets

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

2+ReferencesStructured and connected to the statements they support

Which drugs share a target with Nilofabicin, and which of those have an active Phase 3 trial?

Create a free account or log in to explore the full data card.